title: Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
abstract: OBJECTIVE
  To assess the cost-effectiveness of vortioxetine versus venlafaxine XR (extended-release) in major depressive disorder (MDD) patients in South Korea.
  
  
  METHODS
  A 1-year cost-effectiveness analysis from a limited societal perspective was performed using a combined model consisting of a decision-tree and a Markov model. Patients entered the model when initiating or switching antidepressant treatment following inadequate response to previous treatment. Remission, relapse and recovery were the main health states.
  
  
  RESULTS
  Vortioxetine dominated venlafaxine XR, with quality-adjusted life year (QALY) gains of 0.0131 and cost savings of KRW 623,229/year [US$530/year] from a limited societal perspective. Safety contributed more than efficacy to the incremental QALY gains. More patients were in recovery after initial treatment and after 1 year with vortioxetine (31%, 40%) compared to venlafaxine XR (23%, 36%). Vortioxetine remained dominant in 98% of probabilistic simulations.
  
  
  CONCLUSIONS
  Vortioxetine dominated venlafaxine XR in South Korea and is a relevant treatment option for MDD patients initiating or switching therapy.
authors.affiliation: a College of Pharmacy , Korea University , Sejong , South Korea.
authors.forename: Sang-Eun
authors.initials: SE
authors.lastname: Choi
authors.affiliation: b Lundbeck SAS , Issy-les-Moulineaux , France.
authors.forename: Mélanie
authors.initials: M
authors.lastname: Brignone
authors.affiliation: c Gil Medical Center , Gachon University , Incheon , South Korea.
authors.forename: Seong Jin
authors.initials: SJ
authors.lastname: Cho
authors.affiliation: d School of Medicine , Sungkyunkwan University , Seoul , South Korea.
authors.forename: Hong Jin
authors.initials: HJ
authors.lastname: Jeon
authors.affiliation: e HyeRang , Seoul , South Korea.
authors.forename: Rangrhee
authors.initials: R
authors.lastname: Jung
authors.affiliation: f Mapi Group , Uxbridge , UK.
authors.forename: Rosanne
authors.initials: R
authors.lastname: Campbell
authors.affiliation: g Lundbeck Inc , Deerfield , USA.
authors.forename: Clément
authors.initials: C
authors.lastname: Francois
authors.affiliation: h Lundbeck Singapore Pte Ltd , Singapore.
authors.forename: Dominique
authors.initials: D
authors.lastname: Milea
mesh_terms: D000928:Antidepressive Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D003692:Delayed-Action Preparations; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D008390:Markov Chains; D010879:Piperazines / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D019057:Quality-Adjusted Life Years; D012008:Recurrence; D056910:Republic of Korea; D013440:Sulfides / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000078784:Vortioxetine
chemical_list: D000928:Antidepressive Agents; D003692:Delayed-Action Preparations; D010879:Piperazines; D013440:Sulfides; D000078784:Vortioxetine; D000069470:Venlafaxine Hydrochloride
keywords: Depression; antidepressant; cost-effectiveness; economic; model